Adjuvant aromatase inhibitor therapy and early markers for cardiovascular disease in breast cancer survivors

Autor: Annemiek van Ommen-Nijhof, Judy N. Jacobse, Lars C. Steggink, Joop D. Lefrandt, Jourik A. Gietema, Flora E. van Leeuwen, Michael Schaapveld, Gabe S. Sonke
Přispěvatelé: Damage and Repair in Cancer Development and Cancer Treatment (DARE), Guided Treatment in Optimal Selected Cancer Patients (GUTS), Medical Oncology
Jazyk: angličtina
Rok vydání: 2022
Předmět:
Zdroj: Breast Cancer Research and Treatment, 196. SPRINGER
Breast Cancer Research and Treatment, 196(3), 591-602. Springer New York
ISSN: 0167-6806
Popis: PurposeAromatase inhibitors (AIs) are an important component of the adjuvant treatment of hormone receptor positive breast cancer (BC) but concerns regarding their cardiovascular safety remain. In this cross-sectional study nested in a breast cancer cohort, we investigated the association between AI exposure and early markers for cardiovascular disease in BC survivors.MethodsThe study population consisted of 569 women, who were 5-7 years (n=277) or 10-12 years (n=292) after BC diagnosis. All participants underwent carotid ultrasound, skin autofluorescence measurement and laboratory evaluation. To quantify AI exposure, we obtained the AI ratio by dividing the duration of AI use by the total duration of endocrine therapy (ET). Patients were classified according to their AI ratio into low (no ET or AI ratio 0.60). The association between AI ratio and carotid intima media thickness (cIMT), advanced glycation end products (AGEs) and the presence of dyslipidemia was assessed using linear and logistic regression.Results Median age at study visit was 55.5 years (range 45.2-63.8). Forty percent (n=231) of the study population had used AIs, of whom the majority sequentially with tamoxifen; median duration of AI use was 3.0 years. Mean cIMT and mean AGEs did not differ across AI exposure groups in univariable and multivariable analysis. The occurrence of dyslipidemia did not vary across AI exposure groups. Intermediate AI exposure was associated with more frequent occurrence of the combined endpoint (elevated cIMT, elevated AGEs and/or dyslipidemia). This association, however, was not present in the group with highest AI exposure.ConclusionAI exposure was not associated with cIMT, AGEs or the presence of dyslipidemia. Our results are reassuring for the cardiovascular safety of patients who receive treatment with AIs to reduce the risk of BC recurrence.Trial registration number (clinicaltrials.gov): NCT02485626, June 30, 2015
Databáze: OpenAIRE
Externí odkaz: